GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CV Sciences Inc (OTCPK:CVSI) » Definitions » Beneish M-Score

CV Sciences (CV Sciences) Beneish M-Score : -2.10 (As of Apr. 29, 2024)


View and export this data going back to 2011. Start your Free Trial

What is CV Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.1 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for CV Sciences's Beneish M-Score or its related term are showing as below:

CVSI' s Beneish M-Score Range Over the Past 10 Years
Min: -6.31   Med: -4.59   Max: -0.24
Current: -2.1

During the past 13 years, the highest Beneish M-Score of CV Sciences was -0.24. The lowest was -6.31. And the median was -4.59.


CV Sciences Beneish M-Score Historical Data

The historical data trend for CV Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CV Sciences Beneish M-Score Chart

CV Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.95 -4.91 -4.74 -5.34 -2.10

CV Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.34 -2.38 -3.01 -2.81 -2.10

Competitive Comparison of CV Sciences's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CV Sciences's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CV Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CV Sciences's Beneish M-Score falls into.



CV Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CV Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5697+0.528 * 0.7736+0.404 * 1.3111+0.892 * 0.9876+0.115 * 1.7898
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8162+4.679 * 0.114891-0.327 * 0.6329
=-2.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.43 Mil.
Revenue was 3.801 + 4.089 + 3.966 + 4.148 = $16.00 Mil.
Gross Profit was 1.742 + 1.843 + 1.718 + 1.782 = $7.09 Mil.
Total Current Assets was $7.94 Mil.
Total Assets was $9.20 Mil.
Property, Plant and Equipment(Net PPE) was $0.55 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.24 Mil.
Selling, General, & Admin. Expense(SGA) was $9.75 Mil.
Total Current Liabilities was $6.12 Mil.
Long-Term Debt & Capital Lease Obligation was $0.06 Mil.
Net Income was -0.869 + -0.447 + -1.288 + 5.706 = $3.10 Mil.
Non Operating Income was 0.011 + -0.01 + -0.209 + 0 = $-0.21 Mil.
Cash Flow from Operations was -0.114 + -0.019 + 1.411 + 0.975 = $2.25 Mil.
Total Receivables was $0.77 Mil.
Revenue was 3.869 + 3.751 + 4.138 + 4.447 = $16.21 Mil.
Gross Profit was 1.562 + 1.562 + 1.27 + 1.156 = $5.55 Mil.
Total Current Assets was $11.13 Mil.
Total Assets was $12.74 Mil.
Property, Plant and Equipment(Net PPE) was $0.85 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.99 Mil.
Selling, General, & Admin. Expense(SGA) was $12.09 Mil.
Total Current Liabilities was $13.31 Mil.
Long-Term Debt & Capital Lease Obligation was $0.19 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.431 / 16.004) / (0.766 / 16.205)
=0.026931 / 0.047269
=0.5697

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5.55 / 16.205) / (7.085 / 16.004)
=0.342487 / 0.442702
=0.7736

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (7.938 + 0.546) / 9.2) / (1 - (11.13 + 0.85) / 12.736)
=0.077826 / 0.059359
=1.3111

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=16.004 / 16.205
=0.9876

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.992 / (0.992 + 0.85)) / (0.235 / (0.235 + 0.546))
=0.538545 / 0.300896
=1.7898

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(9.745 / 16.004) / (12.09 / 16.205)
=0.60891 / 0.746066
=0.8162

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.058 + 6.115) / 9.2) / ((0.188 + 13.314) / 12.736)
=0.670978 / 1.060144
=0.6329

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3.102 - -0.208 - 2.253) / 9.2
=0.114891

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

CV Sciences has a M-score of -2.10 suggests that the company is unlikely to be a manipulator.


CV Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of CV Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


CV Sciences (CV Sciences) Business Description

Traded in Other Exchanges
N/A
Address
9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126
CV Sciences Inc is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). The company also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based novel therapeutics.
Executives
William Mccorkle director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Corroon James Michael Jr. director 9530 PADGETT STREET, SUITE 107, SAN DIEGO CA 92126
Maroon Joseph C Md director 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mona Michael Joseph Jr director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Paul Blake director 145 BRANDYWINE PKWY, WEST CHESTER PA 19380
Douglas Jesse Mackay officer: Sr VP Scientific/Regulatory 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Joseph D Dowling officer: Chief Financial Officer 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Joerg Grasser officer: CFO 2688 SOUTH RAINBOW BLVD STE B, LAS VEGAS NV 89146
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Terri F Graham director C/O JACK IN THE BOX INC, 9330 BALVOA AVE, SAN DIEGO CA 92123
Stephen Martin Schmitz director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Gary Sligar director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
James A Mcnulty director C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Larry Phillip Raskin director 1630 FUNNY CIDE DRIVE, WAXHAW NC 28173
Mackay Ventures Inc. other: Member 10% holding group 6325 S. JONES BOULEVARD #500, LAS VEGAS NV 89118

CV Sciences (CV Sciences) Headlines